Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ 94,780	$ (674,780)	$ 73,133
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation	365,334	382,783	351,178
Goodwill impairment	13,078	830,787	0
Equity-based compensation	14,880	22,468	22,397
Change in fair value of warrant liability	(4,021)	(34,482)	(17,158)
Reduction in the carrying amount of operating lease right-of-use assets	32,848	31,873	32,264
Reduction in the carrying amount of finance lease right-of-use assets	11,100	5,938	0
Deferred income tax expense (benefit)	32,049	(62,595)	18,036
Change in fair value of interest rate swaps, net of reclassification adjustment	(367)	(1,801)	(2,936)
Amortization of deferred financing costs	5,666	5,234	5,234
Loss on extinguishment of debt	2,273	0	0
Payment of contingent consideration from an acquisition	(1,850)	0
Other	2,128	350	(285)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(26,217)	(28,862)	(209)
Inventory	(28,065)	15,531	(6,300)
Prepaid and other assets	27,325	(20,305)	(13,143)
Operating lease obligations	(32,934)	(32,428)	(31,213)
Operating liabilities	33,832	40,955	(57,131)
Net cash provided by operating activities	541,839	480,666	373,867
Cash flows from investing activities:
Purchases of equipment and other fixed assets	(306,055)	(337,463)	(391,423)
Payments for business acquisitions, net of cash acquired	(9,536)	(19,687)	(19,017)
Proceeds from the sale of assets	5,316	0	0
Payments for cost method investments	0	(128)	(731)
Net cash used in investing activities	(310,275)	(357,278)	(411,171)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit	253,477	50,000	0
Repayments on long-term debt and lines of credit	(423,477)	(95,000)	(20,000)
Repayments of finance lease obligations	(9,865)	(6,769)	(16,176)
Payments for shares purchased under share repurchase program	0	(29,275)	(13,992)
Payments for tax withholdings from restricted stock vestings and stock option exercises	(2,066)	(5,843)	(3,516)
Payments of contingent consideration and deferred purchase price from acquisitions	(5,298)	(2,535)	(14,493)
Payments relating to the Tax Receivable Agreement	(1,432)	(3,224)	0
Payments of debt financing costs	(6,429)	0	0
Distributions to noncontrolling interests	(5,600)	(2,500)	(2,000)
Proceeds from the exercise of stock options	742	587	2,510
Proceeds received in connection with employee stock purchase plan	999	2,031	1,616
Net cash used in financing activities	(198,949)	(92,528)	(66,051)
Net increase (decrease) in cash	32,615	30,860	(103,355)
Cash at beginning of period	77,132	46,272	149,627
Cash at end of period	109,747	77,132	46,272
Supplemental disclosures:
Cash paid for interest	122,072	126,228	108,885
Cash paid for income taxes, net of refunds	14,139	14,756	14,949
Noncash investing and financing activities:
Equipment acquired under finance lease obligations	0	0	1,335
Unpaid equipment and other fixed asset purchases at end of period	56,123	35,867	24,221
Operating leases	35,871	22,000	22,543
Operating lease obligations	(35,871)	(22,000)	(22,543)
Write-off of assets subject to operating lease obligations	(6,653)	(14,675)	(8,532)
Write-off of operating lease obligations	6,653	14,675	8,532
Assets subject to finance lease obligations	17,871	32,101	0
Finance lease obligations	(17,871)	(32,101)	0
Write-off of assets subject to finance lease obligations	(513)	0	0
Write-off of finance lease obligations	513	0	0
Deferred purchase price in connection with acquisitions	$ 0	$ 137	$ 457